Sarasota, FL -- (SBWIRE) -- 03/13/2019 -- According to the report, global erectile dysfunction drugs market was valued at approximately USD 4.82 billion in 2017 and is expected to generate revenue of around USD 7.10 billion by end of 2024, growing at a CAGR of around 5.70% between 2018 and 2024.

The demand for erectile dysfunction drugs is highly growing due to a high incidence rate of chronic diseases including hypertension, neurogenic and psychological disorders, and diabetes. Besides these, rising aged population, alcoholism, sedentary lifestyles, and smoking greatly increases the risk of erectile dysfunction. Growing adoption of these poor lifestyle choices leads to the overall growth of the market for erectile dysfunction drugs. Other factors like patient awareness and education, a growing number of campaigns by government and non-government organizations worldwide to make patients aware of the disease are also other factors responsible for the market growth of erectile dysfunction drugs.

DOWNLOAD FREE PDF BROCHURE @ http://bit.ly/2UwE3tF

The erectile dysfunction drugs market is divided on the basis of drug which is further divided into Sildenafil Citrate (Viagra), Mirodenafil (Mvix), Vardenafil (Levitra/ Staxyn), Tadalafil (Cialis), Udenafil (Zydena), Stendra/ Spedra (Avanafil), Lodenafil Carbonate (Helleva), and others. Viagra is one of the most widely distributed products worldwide. Viagra dominated the market in terms of revenue and was valued at over USD 2.4 billion in 2014. Though its patent expires by 2019 in the U.S., it is anticipated to account for almost 27% of the market share by the end of 2024 due to its brand loyalty worldwide.

The erectile dysfunction drugs market is categorized on the basis of mode of administration into oral medications, topical medications, injections, and others. The oral medication segment is likely to dominate the market since the first line of treatment or medication for erectile dysfunction comprises of oral medication. Oral phosphodiesterase type 5 inhibitors are commonly used in erectile dysfunction drugs across the globe. Viagra and other PDE 5 inhibitors such as Cialis and Levitra/ Staxyn are extensively consumed for erectile dysfunction treatment thus propelling the market for oral medications.

Based on the distribution channel, the market is segmented into online sales, hospital pharmacies, and retail pharmacies. The online sales segment is expected to grow at the highest CAGR over the forecast period. The presence of online sales is a blessing in disguise for several patients who are conscious about visiting a retail pharmacy store to purchase drugs for erectile dysfunction and other sexual wellness products.

Get FREE Sample Research Report @ http://bit.ly/2u3Ny7L

Regionally, the erectile dysfunction drugs market is segmented into Europe, North America, Asia Pacific, the Middle East & Africa, and Latin America. North America is the leading contributor of the erectile dysfunction drugs market owing to the presence of established healthcare infrastructure, high demand for these drugs, and growing research and development initiatives pertaining to the new novel drug molecule development. Also, high awareness among the people about the disease, prolongation of patent exclusivity rights for Viagra in the U.S. and presence of a large number of players in the region are the key factors contributing to the growth of erectile dysfunction drugs in this region.

Some of the leading players in erectile dysfunction drugs market include Apricus Biosciences, Bayer AG, Cristália, Eli Lilly and Company, Inc., Pfizer, Inc., Dong-A-Pharmaceutical Co., Ltd., S.K. Chemicals Co., Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd., and Meda Pharmaceuticals, Inc. Pfizer, Inc. accounted for almost 40.0% market share in 2012. Yet, the market share of the company is likely to decline due to the patent expiration of Viagra in 2019. However, generics are expected to propel industrial growth. In addition to mergers, acquisitions and collaborations activities, post-patent expiration, and geographic expansion are likely to keep the industry rivalry at higher levels in the forecast period.

This report segments the global erectile dysfunction drugs market as follows:

Global Erectile Dysfunction Drugs Market: Drug Segment Analysis

Sildenafil Citrate (Viagra)
Vardenafil (Levitra/ Staxyn)
Tadalafil (Cialis)
Udenafil (Zydena)
Lodenafil Carbonate (Helleva)
Stendra/ Spedra (Avanafil)
Mirodenafil (Mvix)
Others

Global Erectile Dysfunction Drugs Market: Mode of Administration Segment Analysis

Oral Medications
Topical Medications
Injections
Others

Global Erectile Dysfunction Drugs Market: Distribution Channel Segment Analysis

Hospital Pharmacies
Retail Pharmacies
Online Sales

Global Erectile Dysfunction Drugs Market: Regional Segment Analysis

North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
The Middle East and Africa

GET FREE PDF BROCHURE @ http://bit.ly/2UwE3tF

About Zion Market Research
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.